Myelodysplastic Syndromes (MDS)

In 2008 Dr. Risitano received a grant for the research project, "Genetic Fingerprint of Complement and Complement-related Genes in PNH: Relationship with Pathophysiology, Clinical Manifestations (including Thrombosis) and Response to Eculizamab PNH Foundation." We recently caught up with Dr. Risitano and asked how the grant helped him add to the understanding of bone marrow failure disease and where his current research is. The grant contributed to allowing Dr. Risitano to perform research that has unraveled novel mechanisms of disease in PNH. Risitano and his team were first able to

Dr. Eric Padron is a junior investigator, having completed his fellowship in hematology/oncology at the Moffitt Cancer Center in Florida. He describes his area of interest in bone marrow failure disease as focused on Chronic Myelomonocytic Leukemia (CMML), which is related to Myelodysplastic Syndromes (MDS). Although he looks forward to his weekly clinic day when he is able to see patients with MDS, he also notes that the two year fellowship he received through the Edward P. Evans Foundation was invaluable in allowing him to protect some of his time from other clinical duties, and focus on his

Dr. Hetty Caraway received her medical degree from the University of Massachusetts Medical School in Worcester, Massachusetts. She completed her internship and residency in internal medicine, and her fellowship in medical oncology at Johns Hopkins University in Baltimore. In addition to her medical training, Dr. Carraway earned an MBA from the Carey Business School at Johns Hopkins University in the Business of Health. She is currently a Staff Physician at the Taussig Cancer Institute in the Division of Hematologic Oncology and Blood Disorders at the Cleveland Clinic. Dr. Carraway is American

Valeria Santini is an Associate Professor of Hematology at the University of Florence Medical School in Florence Italy, where she received her degree in Medicine and Postgraduate diploma in hematology (cum laude). She worked as an EORTC fellow in experimental hematology from 1988 to 1991 at the Dr. den Hoed Kliniek, Erasmus University, Rotterdam. In 1999 she worked in the Department of Leukemia at MD Anderson Cancer Center, University of Texas, Houston. Her scientific interests and publications are focused on maturation induction and therapeutic targeting of epigenetics modifications, myeloid

Dr. Navada is an assistant professor in the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York City. She attended medical school at the University of Illinois at Chicago. Subsequently, she did an Internal Medicine Residency at the University of Michigan in Ann Arbor prior to completing a hematology/oncology fellowship at Mount Sinai. She is currently completing a Masters of Science in Clinical Research in the graduate school at Mount Sinai. Her primary clinical and research interests are myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the